Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS.

Korean J Intern Med. 2019 Sep;34(5):1116-1124. doi: 10.3904/kjim.2018.011. Epub 2018 Jun 29.

2.

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.

Zhou J, Zheng J, Zhang X, Zhao J, Zhu Y, Shen Q, Wang Y, Sun K, Zhang Z, Pan Z, Shen Y, Zhou J.

BMC Cancer. 2018 Jan 3;18(1):10. doi: 10.1186/s12885-017-3720-8.

3.

Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.

Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, Sakao Y, Hida T, Yatabe Y.

Lung Cancer. 2016 Jul;97:43-7. doi: 10.1016/j.lungcan.2016.04.006. Epub 2016 Apr 23.

PMID:
27237026
4.

Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.

Zhang L, Jiang T, Li X, Wang Y, Zhao C, Zhao S, Xi L, Zhang S, Liu X, Jia Y, Yang H, Shi J, Su C, Ren S, Zhou C.

Cancer. 2017 Aug 1;123(15):2927-2935. doi: 10.1002/cncr.30677. Epub 2017 Mar 27.

5.

Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study.

Xing P, Ma D, Wang Q, Hao X, Wang M, Wang Y, Shan L, Xin T, Liang L, Liang H, Du Y, Zhang Z, Li J.

Chin J Cancer Res. 2019 Jun;31(3):481-488. doi: 10.21147/j.issn.1000-9604.2019.03.10.

6.

Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.

Watanabe S, Hayashi H, Okamoto K, Fujiwara K, Hasegawa Y, Kaneda H, Tanaka K, Takeda M, Nakagawa K.

Clin Lung Cancer. 2016 Nov;17(6):528-534. doi: 10.1016/j.cllc.2016.05.001. Epub 2016 May 18.

PMID:
27318655
7.

Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.

Cadranel J, Park K, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Swallow E, Galebach P, Kageleiry A, Stein K, Degun R, Zhang J.

Lung Cancer. 2016 Aug;98:9-14. doi: 10.1016/j.lungcan.2016.05.004. Epub 2016 May 10.

PMID:
27393500
8.

Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.

Xu H, Yang G, Yang L, Yang Y, Ma D, Li J, Hao X, Xing P, Wang Y.

Thorac Cancer. 2019 May;10(5):1096-1102. doi: 10.1111/1759-7714.13050. Epub 2019 Mar 28.

9.

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.

Gainor JF, Tan DS, De Pas T, Solomon BJ, Ahmad A, Lazzari C, de Marinis F, Spitaleri G, Schultz K, Friboulet L, Yeap BY, Engelman JA, Shaw AT.

Clin Cancer Res. 2015 Jun 15;21(12):2745-52. doi: 10.1158/1078-0432.CCR-14-3009. Epub 2015 Feb 27.

10.

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.

Tan DS, Araújo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, Liu G.

J Thorac Oncol. 2016 Sep;11(9):1550-7. doi: 10.1016/j.jtho.2016.05.029. Epub 2016 Jun 8.

11.

Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.

Cui S, Zhao Y, Dong L, Gu A, Xiong L, Qian J, Zhang W, Niu Y, Pan F, Jiang L.

Cancer Med. 2016 Jun;5(6):1013-21. doi: 10.1002/cam4.659. Epub 2016 Feb 16.

12.

Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.

Bedas A, Peled N, Maimon Rabinovich N, Mishaeli M, Shochat T, Zer A, Rotem O, Allen AM, Bar J, Dudnik E; On behalf of the Israel Lung Cancer Group.

Oncol Res Treat. 2019;42(5):275-282. doi: 10.1159/000499086. Epub 2019 Apr 5.

PMID:
30955009
13.

Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.

Su Y, Long X, Song Y, Chen P, Li S, Yang H, Wu P, Wang Y, Bing Z, Cao Z, Cao L, Wu Y, Zhang Z, Liu J, Li B, Xiang J, Ma K, Zhang T, Zhang L, Mao X, Liu H, Xing P, Liang N.

Target Oncol. 2019 Apr;14(2):159-168. doi: 10.1007/s11523-019-00631-x.

PMID:
30895431
14.

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country.

Noronha V, Ramaswamy A, Patil VM, Joshi A, Chougule A, Kane S, Kumar R, Sahu A, Doshi V, Nayak L, Mahajan A, Janu A, Prabhash K.

PLoS One. 2016 Sep 16;11(9):e0160752. doi: 10.1371/journal.pone.0160752. eCollection 2016. Erratum in: PLoS One. 2016 Dec 9;11(12 ):e0168221.

15.

Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.

Miloš P, Jana S, Vítězslav K, Monika Š, Leona K, Jaromír R, Renata C, Markéta Č, Andrea B, Juraj K, Michal H, Milada Z, Marek K, Helena Č, Martin S.

Klin Onkol. Spring 2018;31(3):207-212. doi: 10.14735/amko2018207.

PMID:
30441974
16.

New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.

Dubey AP, Pathi N, Viswanath S, Rathore A, Pathak A, Sud R.

Indian J Cancer. 2017 Jan-Mar;54(1):203-208. doi: 10.4103/ijc.IJC_72_17.

17.

Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.

Lei YY, Yang JJ, Zhang XC, Zhong WZ, Zhou Q, Tu HY, Tian HX, Guo WB, Yang LL, Yan HH, Chen HJ, Xie Z, Su J, Han JF, Wu YL.

Clin Lung Cancer. 2016 May;17(3):223-31. doi: 10.1016/j.cllc.2015.09.002. Epub 2015 Sep 21.

PMID:
26454342
18.

Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib.

Ma D, Zhang Y, Xing P, Hao X, Wang M, Wang Y, Shan L, Xin T, Liang H, Du Y, Zhang Z, Liang L, Li J.

Thorac Cancer. 2019 May;10(5):1213-1219. doi: 10.1111/1759-7714.13071. Epub 2019 Apr 16.

19.

Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.

Lei YY, Yang JJ, Zhong WZ, Chen HJ, Yan HH, Han JF, Yang LL, Wu YL.

J Thorac Dis. 2015 Jul;7(7):1181-8. doi: 10.3978/j.issn.2072-1439.2015.06.04.

20.

Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea.

Lim SH, Yoh KA, Lee JS, Ahn MJ, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Galebach P, Lee D, Stein K, Degun R, Park K.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e239-e245. doi: 10.1111/ajco.12645. Epub 2017 Apr 16.

PMID:
28419723

Supplemental Content

Support Center